Gamida Cell Ltd. $50 Million Initial Public Offering

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the NASDAQ Global Market under the symbol “GMDA.”

Based in Jerusalem, Israel, Gamida Cell is a clinical stage biopharmaceutical company that leverages its proprietary nicotinamide-, or NAM-, based cell expansion technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases.

The Davis Polk corporate team included partners Michael Kaplan and Derek Dostal and associates Joseph S. Payne and Sana Bargach. The tax team included partner Rachel D. Kleinberg and associate Gil Savir. The intellectual property and technology team included partner David R. Bauer and associate Jesse L. Hallock. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices.